Foghorn therapeutics provides financial update for 2024 and 2025 strategic outlook

First-in-class oral selective smarca2 (brm) inhibitor fhd-909 (ly4050784) continues enrollment in phase 1 trial for smarca4 (brg1) mutated cancers, with non-small cell lung cancer (nsclc) as the primary target population
FHTX Ratings Summary
FHTX Quant Ranking